08:45 AM EDT, 05/13/2024 (MT Newswires) -- Fulcrum Therapeutics ( FULC ) said Monday it has signed a deal with Sanofi ( SNY ) for losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD).

Under the terms of the deal, Sanofi ( SNY ) will have exclusive rights to commercialize losmapimod outside the US, while Fulcrum retains US rights, Fulcrum said.

The company said it would receive an $80 million upfront payment and could earn up to $975 million in milestones, plus royalties. Both companies will share future global development costs equally, Fulcrum added.

Fulcrum's shares were up nearly 14% in recent Monday premarket activity.

Price: 8.50, Change: +1.03, Percent Change: +13.83